Adherent cells from adipose or placenta tissues and use thereof in therapy
A method of treating ischemia in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of adherent cells of a tissue selected from the group consisting of a placenta and an adipose tissue, thereby treating the ischemia in the subject. A method of treating a medical condition requiring connective tissue regeneration and/or repair is also disclosed.
1. A method of treating ischemia peripheral arterial disease (PAD) in a subject in need of treatment for PAD, comprising:
administering to the subject a therapeutically effective amount of undifferentiated placenta-derived adherent stromal cells,
wherein the adherent stromal cells do not express CD34;
thereby treating the PAD.
2. The method of claim 1 , wherein at least 10% of said cells are at a proliferative phase.
3. The method of claim 1 , wherein said peripheral arterial disease (PAD) is critical limb ischemia (CLI).
4. The method of claim 1 , wherein said cells are propagated in three-dimensional (3D) culturing conditions.
5. The method of claim 4 , wherein said three-dimensional (3D) culturing conditions comprise a 3D bioreactor.
6. The method of claim 4 , wherein said three-dimensional (3D) culturing conditions are effected under perfusion.
7. The method of claim 4 , wherein said three-dimensional (3D) culturing conditions comprise an adherent material selected from the group consisting of a polystyrene, a polyester, and a polypropylene.
8. The method of claim 1 , wherein culturing of said cells is effected for at least 3 days.
9. The method of claim 1 , wherein culturing of said cells is effected until at least 10% of said cells are proliferating.
10. The method of claim 4 , wherein said cells express a marker selected from the group consisting of CD73, CD90, CD29 and CD105.
11. The method of claim 4 , wherein said cells do not express a marker selected from the group consisting of CD3, CD4, CD45, CD80, HLA-DR, CD11b, CD14, CD19, and CD79.
12. The method of claim 6 , wherein said perfusion rate is adjusted in order to maintain a constant glucose concentration in the culture medium.
13. The method of claim 12 , wherein said constant glucose concentration is about 550 mg/L.
14. The method of claim 1 , wherein said cells are propagated in two-dimensional (2D) culturing conditions.
15. The method of claim 14 , wherein said cells express a marker selected from the group consisting of CD90, CD105, CD73 and CD29.